Goldman Sachs moved Structure Therapeutics (GPCR) to Buy rating and $102 price target from Early Stage Biotech. The company’s oral small molecule GLP-1 aleniglipron has shown to be competitive against Eli Lilly’s (LLY) orforglipron, the analyst tells investors in a research note. The firm views Structure’s Phase 2 data as “de-risking” and sees scarcity value for the shares. Structure has a an oral small molecule that could be second to market only behind Lilly’s orforglipron, contends Goldman.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
- Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
- Structure Therapeutics rises 14.1%
- Validating IP, Extending Runway: Why Structure Therapeutics’ Oral GLP‑1 Platform Supports a Buy Rating
- Structure Therapeutics inks major GLP-1 licensing deal